AUSTIN, TX—Sheena Jonathan, co-founder and director of Natera, Inc. (NASDAQ:NTRA), a company whose stock has surged over 158% in the past year and currently commands a market capitalization of $22.7 billion, recently executed a series of stock transactions, as disclosed in a recent SEC filing. On January 22, Jonathan sold 971 shares of Natera's common stock at prices ranging from $164.9488 to $171.9091 per share. The total value of these sales amounted to approximately $160,214. The transaction occurred with the stock trading near its 52-week high of $183, according to InvestingPro data.
The sales were conducted to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Jonathan holds 261,745 shares of Natera's common stock directly. Additionally, she retains indirect ownership of 44,782 shares through the Caraluna 1 and Caraluna 2 trusts, although she disclaims beneficial ownership of these securities.
These transactions are part of Jonathan's planned financial activities and were executed in compliance with Rule 10b5-1(c) under the Exchange Act.
In other recent news, Natera Inc . has broadened its patent infringement litigation against NeoGenomics (NASDAQ:NEO), Inc. over the RaDaR assay. The company has also reported record Q3 revenue of $439.8 million, a 64% year-over-year increase, and performed 137,000 oncology tests, marking a 54% rise from the previous year. In response to these developments, analyst firms TD (TSX:TD) Cowen, Baird, and Jefferies have maintained favorable ratings on Natera's stock and raised their price targets.
In other company news, Natera has faced a setback in a false advertising lawsuit against Guardant Health (NASDAQ:GH) but plans to request the court to overturn the ruling. The company has also amended an agreement with Dr. Rabinowitz, the Executive Chairman, to continue his role under specific conditions.
These are among the recent developments that have been shaping the trajectory of Natera Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.